The Full Wiki

More info on JNJ-7777120

JNJ-7777120: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

JNJ-7777120
Systematic (IUPAC) name
5-chloro-2-[(4-methylpiperazin-1-yl)carbonyl]-1 H-indole
Identifiers
CAS number 459168-41-3
ATC code  ?
PubChem 4908365
Chemical data
Formula C 14H16ClN3O 
Mol. mass 277.749 g/mol
SMILES eMolecules & PubChem
Synonyms 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

JNJ-7777120 is a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H4 receptor.[1] It has antiinflammatory effects,[2] and has been demonstrated to be superior to traditional antihistamines in the treatment of pruritus (itching).[3]

References

  1. ^ Jiang W, Lim HD, Zhang M, et al. (July 2008). "Cloning and pharmacological characterization of the dog histamine H(4) receptor". Eur. J. Pharmacol.. doi:10.1016/j.ejphar.2008.06.095. PMID 18639542. http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(08)00709-7.  
  2. ^ Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, Edwards JP, Karlsson L. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. Journal of Pharmacology and Experimental Therapeutics. 2004 Apr;309(1):404-13. PMID 14722321
  3. ^ Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. Journal of Allergy and Clinical Immunology. 2007 Jan;119(1):176-83. PMID 17208599
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message